228 related articles for article (PubMed ID: 10080609)
1. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Haraf DJ; Kies M; Rademaker AW; Stenson K; Mittal B; Pelzer H; Wenig B; Witt ME; Sulzen L; Weichselbaum RR; Vokes EE
J Clin Oncol; 1999 Feb; 17(2):638-44. PubMed ID: 10080609
[TBL] [Abstract][Full Text] [Related]
2. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Kies MS; Haraf DJ; Rosen F; Stenson K; List M; Brockstein B; Chung T; Mittal BB; Pelzer H; Portugal L; Rademaker A; Weichselbaum R; Vokes EE
J Clin Oncol; 2001 Apr; 19(7):1961-9. PubMed ID: 11283128
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
[TBL] [Abstract][Full Text] [Related]
4. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Taylor SG; Murthy AK; Vannetzel JM; Colin P; Dray M; Caldarelli DD; Shott S; Vokes E; Showel JL; Hutchinson JC
J Clin Oncol; 1994 Feb; 12(2):385-95. PubMed ID: 8113846
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
[TBL] [Abstract][Full Text] [Related]
7. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Ferreli L; Camboni P; Lusso MR; Mocci M; Madeddu C; Mura L; Mudu MC; Proto E; Tore G; Mura M; Macciò A; Ferreli A; Amichetti M
Oncol Rep; 2003; 10(3):759-66. PubMed ID: 12684655
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Garden AS; Harris J; Vokes EE; Forastiere AA; Ridge JA; Jones C; Horwitz EM; Glisson BS; Nabell L; Cooper JS; Demas W; Gore E
J Clin Oncol; 2004 Jul; 22(14):2856-64. PubMed ID: 15254053
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Vokes EE; Panje WR; Schilsky RL; Mick R; Awan AM; Moran WJ; Goldman MD; Tybor AG; Weichselbaum RR
J Clin Oncol; 1989 Jun; 7(6):761-8. PubMed ID: 2715806
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
[TBL] [Abstract][Full Text] [Related]
13. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Cohen EE; Haraf DJ; List MA; Kocherginsky M; Mittal BB; Rosen F; Brockstein B; Williams R; Witt ME; Stenson KM; Kies MS; Vokes EE
J Clin Oncol; 2006 Jul; 24(21):3438-44. PubMed ID: 16849759
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Kohno N; Kitahara S; Tamura E; Tanabe T
Oncology; 2002; 63(3):226-31. PubMed ID: 12381901
[TBL] [Abstract][Full Text] [Related]
15. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
[TBL] [Abstract][Full Text] [Related]
16. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Vokes EE; Stenson K; Rosen FR; Kies MS; Rademaker AW; Witt ME; Brockstein BE; List MA; Fung BB; Portugal L; Mittal BB; Pelzer H; Weichselbaum RR; Haraf DJ
J Clin Oncol; 2003 Jan; 21(2):320-6. PubMed ID: 12525525
[TBL] [Abstract][Full Text] [Related]
17. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
Urba SG; Forastiere AA; Wolf GT; Esclamado RM; McLaughlin PW; Thornton AF
J Clin Oncol; 1994 May; 12(5):946-53. PubMed ID: 8164046
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
Abitbol AA; Schwade JG; Lewin AA; Sridhar K; Brandon AH; Markoe AM; Casiano RR; Houdek PV; Serago C; Miller DJ
Am J Clin Oncol; 1992 Jun; 15(3):250-5. PubMed ID: 1590280
[TBL] [Abstract][Full Text] [Related]
19. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Argiris A; Haraf DJ; Kies MS; Vokes EE
Oncologist; 2003; 8(4):350-60. PubMed ID: 12897332
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Salama JK; Haraf DJ; Stenson KM; Blair EA; Witt ME; Williams R; Kunnavakkam R; Cohen EE; Seiwert T; Vokes EE
Ann Oncol; 2011 Oct; 22(10):2304-9. PubMed ID: 21330337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]